Non -Interventional Study-Palliative Therapy of Multiple Myeloma With a Combination of Lenalidomide and Dexamethasone (REVLIMID-NIS)

iOMEDICO

Status: Completed

Conditions: Multiple Myeloma

Study type: Observational

Funder types: Industry

Identifiers

NCT00911105

IOM-0810

Details and patient eligibility

About

Purpose of this non-interventional study is the documentation of efficacy and safety data of multiple myeloma therapy with a combined treatment of Lenalidomide and Dexamethasone in daily routine practice.

Enrollment: 101 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with multiple myeloma with at least one previous therapy.
• 18 years or older
• Signed, written informed consent

Exclusion criteria

• Pregnancy or nursing
• All other exclusion criteria listed in SmPC (summary of product characteristics)

Trial design

101 participants in 1 patient group

Patients with multiple myeloma

Description:

Patients with multiple myeloma receiving second line therapy or higher.